Angiotensin II for Septic Shock
(ANGIO-ED Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: University of Iowa

No Placebo Group

Prior Safety Data

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED

Eligibility Criteria

This trial is for a small group of 20 patients who arrive at the emergency department with septic shock and need immediate support to maintain blood pressure. Participants must be in a condition where they can receive angiotensin II within three hours after starting norepinephrine, a common drug used to treat low blood pressure.

Inclusion Criteria

I need norepinephrine to maintain my blood pressure after receiving enough fluids.

I am currently on IV antibiotics or will be starting them soon.

Can provide written informed consent (or legally authorized representative)

+1 more

Exclusion Criteria

I have had a condition where my intestines did not get enough blood.

I have had a recent heart attack or related condition.

Expected lifespan of <12 hours

+5 more

Participant Groups

The study is testing if giving angiotensin II early on can help treat septic shock in patients who have just arrived at the emergency department. It's a pilot study, which means it's an initial test before larger studies are done.

1Treatment groups

Experimental Treatment

Group I: Angiotensin II InfusionExperimental Treatment1 Intervention

Angiotensin II is already approved in United States for the following indications:

🇺🇸 Approved in United States as Giapreza for: